Bausch Health Companies Inc.(BHC) (Q2FY23)
Stock Performance – Bausch Health stock price showed an upward trend in the past 3-months. It gave 4.32% returns during the period. The price increased by 8.12% in past 1-year. The stock has a 52-week high of $471.08 and its 52-week low is $163.42.
In the past 3 years, the stock has decreased by 55.09%. BHC has a 50-day moving Avg. and 200-day moving Avg. of $8.73 and $7.91, respectively.
Revenue Performance – BHC revenues were $2,167mn and $1,967mn for Q2FY23 and Q2FY22, respectively, an increase of $200mn, or 10%. The increase was primarily due to growth in the Bausch + Lomb, Salix, Solta Medical and International segments.
Company Guidance for FY23 – BHC expect revenues of $8.45 – $8.65bn, and excl. B+L of $4.50 – $4.65bn for FY23. Adjusted EBITDA is expected to be $3.00 – $3.15bn.
The company is demonstrating strong business performance with an 11% increase in revenues, which includes organic growth. Notably, key segments such as Salix, International, and Solta are all experiencing double-digit growth.
This report is useful for M&A, business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.
– Enterprise Value
– CrispIdea Forecast
– CrispIdea Segment Forecast
– Economic Value Added Analysis
– PE Band Comparison
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum
Actual & Historical Performance
– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– Price Performance
Stock Price Performance
No of Pages: 35
To download the previous quarter’s equity/report CLICK HERE
To Download other equity/reports CLICK HERE
Follow our LinkedIn page for more updates.